ES2038747T3 - Compuestos antineoplasicos. - Google Patents

Compuestos antineoplasicos.

Info

Publication number
ES2038747T3
ES2038747T3 ES198888300064T ES88300064T ES2038747T3 ES 2038747 T3 ES2038747 T3 ES 2038747T3 ES 198888300064 T ES198888300064 T ES 198888300064T ES 88300064 T ES88300064 T ES 88300064T ES 2038747 T3 ES2038747 T3 ES 2038747T3
Authority
ES
Spain
Prior art keywords
compounds
och3
substances
antineoplasic
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888300064T
Other languages
English (en)
Inventor
George R. Pettit
Sheo Bux Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University ASU
Original Assignee
Arizona State University ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University ASU filed Critical Arizona State University ASU
Application granted granted Critical
Publication of ES2038747T3 publication Critical patent/ES2038747T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE HAN AISLADO NUEVOS COMPUESTOS ANTINEOPLASTICOS, ESTRUCTURALMENTE DILUCIDADOS Y SINTETIZADOS, QUE TIENEN LA FORMULA ESTRUCTURAL (I) O (II), DONDE R1 ES OH U OCH3; R2 ES H U OCH3; O R1R2 ES -OCH2O-, R3 ES H U OH; Y R4 ES OH U OCH3, Y DONDE LA CONFIGURACION DEL DOBLE ENLACE EN LOS COMPUESTOS DE FORMULA (I) ES CIS. ESTAS SUSTANCIAS SE HAN DENOMINADO A-1, A-2, A-3, B-1, B-2, B-3 Y B-4 COMBRETASTAINA. SE DESCRIBEN PREPARACIONES FARMACEUTICAS QUE CONTIENEN LAS SUSTANCIAS Y METODOS PARA TRATAR UN HUESPED CON UN TUMOR NEOPLASTICO CON LA PREPARACION.
ES198888300064T 1987-01-06 1988-01-06 Compuestos antineoplasicos. Expired - Lifetime ES2038747T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59087A 1987-01-06 1987-01-06

Publications (1)

Publication Number Publication Date
ES2038747T3 true ES2038747T3 (es) 1993-08-01

Family

ID=21692158

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888300064T Expired - Lifetime ES2038747T3 (es) 1987-01-06 1988-01-06 Compuestos antineoplasicos.

Country Status (8)

Country Link
US (2) US5409953A (es)
EP (1) EP0276051B1 (es)
JP (1) JP2558131B2 (es)
AT (1) ATE66452T1 (es)
CA (1) CA1338645C (es)
DE (1) DE3864269D1 (es)
ES (1) ES2038747T3 (es)
GR (1) GR3003111T3 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
IT1256354B (it) * 1992-08-31 1995-12-01 Francesca Pelizzoni Derivati della combretastatina ad attivita' anti-tumorale e procedimento per la loro preparazione
FR2728570B1 (fr) * 1994-12-23 1997-04-11 Synthelabo Derives de 1-oxo-2-(phenylsulfonylamino)pentylpiperidine, leur preparation et leur application en therapeutique
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
HUP0102521A3 (en) 1998-04-03 2003-08-28 Ajinomoto Kk Antitumor agents comprising a stilbene derivative and a platinum coordination compound
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6624197B1 (en) 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6245814B1 (en) 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6448450B1 (en) * 1998-05-08 2002-09-10 Calyx Therapeutics, Inc. 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
JP2002537262A (ja) * 1999-02-18 2002-11-05 オキシジェン，インコーポレイティド 血管破壊のターゲッティングに使用するための組成物および方法
EP1832290A3 (en) * 1999-02-18 2010-11-17 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
EP1185559A2 (en) 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20020002200A1 (en) * 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6525093B1 (en) * 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
ATE368046T1 (de) * 2000-03-10 2007-08-15 Univ Baylor Tubulin bindende liganden
WO2001081355A1 (en) * 2000-04-27 2001-11-01 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona,Acting For And On Behalf Of Arizona State University Combretastatin a-1 phosphate and combretastatin b-1 phosphate prodrugs
WO2002006279A1 (en) 2000-07-17 2002-01-24 Oxigene Inc Efficient method of synthesizing combretastatin a-4 prodrugs
GB0031263D0 (en) * 2000-12-21 2001-01-31 Paterson Inst For Cancer Res Materials and methods for synthesizing stilbenes
EP1351912A2 (en) * 2000-12-21 2003-10-15 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
JP2004523517A (ja) 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
AU2002246756A1 (en) 2000-12-26 2002-08-06 Bristol-Myers Squibb Company Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
US7547686B2 (en) 2001-06-15 2009-06-16 Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University Combretastatin A-3 prodrug
WO2003006002A1 (en) * 2001-07-13 2003-01-23 Oxigene, Inc. Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US7105695B2 (en) * 2001-12-21 2006-09-12 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthesis of combretastatin A-2 prodrugs
DK1537146T3 (da) 2002-07-15 2011-04-04 Univ Texas Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
US20060100179A1 (en) * 2002-08-14 2006-05-11 Pero Ronald W Compositions and methods for use in targeting vascular destruction
WO2004078126A2 (en) * 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
GB0306908D0 (en) * 2003-03-26 2003-04-30 Angiogene Pharm Ltd Bioreductively activated stilbene prodrugs
AU2006214164B2 (en) 2005-02-17 2010-12-09 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
EP1976505A1 (en) * 2005-11-14 2008-10-08 Abraxis BioScience, Inc. Combretastatin derivatives and related therapeutic methods
JP2009531421A (ja) 2006-03-28 2009-09-03 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 置換スチルベン及びその類似体の調製のための単一工程マイクロ波誘導方法
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
AU2008326251B2 (en) * 2007-11-21 2014-03-06 Mateon Therapeutics, Inc. Method for treating hematopoietic neoplasms
CN101723813A (zh) * 2008-10-15 2010-06-09 上海华理生物医药有限公司 一种乙氧基二苯乙烷衍生物及其制备方法和用途
WO2010113005A2 (en) 2009-03-27 2010-10-07 Council Of Scientific & Industrial Research One pot multicomponent synthesis of some novel hydroxy stilbene derivatives with alpha, beta-carbonyl conjugation under microwave irradiation
CN103765212A (zh) 2011-06-27 2014-04-30 杰克逊实验室 治疗癌症和自体免疫性疾病的方法和组合物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP6175399B2 (ja) * 2014-03-31 2017-08-02 静岡県公立大学法人 スチルベン類縁化合物を有効成分とする抗炎症剤
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA463336A (en) * 1950-02-21 Eli Lilly And Company Method of producing dialkoxy stilbenes
US2496968A (en) * 1945-10-05 1950-02-07 Burroughs Wellcome Co Alpha:beta:2:2'-tetramethyl-4:4'-dihydroxystilbene
US3198840A (en) * 1960-05-11 1965-08-03 Armour Pharma Derivatives of diphenyl synthetic estrogens
US3293307A (en) * 1963-12-23 1966-12-20 Sun Oil Co Preparation of substituted ethanes
GB1046380A (en) * 1964-07-06 1966-10-26 American Cyanamid Co New hypocholesteremic compositions
US3577230A (en) * 1968-10-18 1971-05-04 Arizona Chem Process of applying novel algicides
US3968234A (en) * 1975-03-05 1976-07-06 The United States Of America As Represented By The Secretary Of Agriculture Cinnamyl-sesamol derivatives as insect chemosterilants
DE2658307C2 (de) * 1976-12-22 1979-03-15 Klinge Pharma Gmbh & Co, 8000 Muenchen Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
US4482728A (en) * 1981-11-05 1984-11-13 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxbenzenes in insect population control
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
DE3866371D1 (de) * 1987-02-13 1992-01-09 Ciba Geigy Ag Diphenylaethylen-derivate.
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof

Also Published As

Publication number Publication date
DE3864269D1 (de) 1991-09-26
US5569786A (en) 1996-10-29
GR3003111T3 (en) 1993-02-17
EP0276051A3 (en) 1988-11-30
JPS63233939A (ja) 1988-09-29
EP0276051B1 (en) 1991-08-21
ATE66452T1 (de) 1991-09-15
JP2558131B2 (ja) 1996-11-27
CA1338645C (en) 1996-10-15
EP0276051A2 (en) 1988-07-27
US5409953A (en) 1995-04-25

Similar Documents

Publication Publication Date Title
ES2038747T3 (es) Compuestos antineoplasicos.
AU599792B2 (en) Anti-parkinsonian indolone derivatives
HU206701B (en) Process for producing substituted flavonoid derivatives and salts and pharmaceutical compositions containing these compounds
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
AU611113B2 (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
BG44379A3 (en) Method for preparing of 9- chlor- 1, 5- benzothiazepine derivatives
EP0331092A3 (en) Alpha-amino-carboxylic-acid derivatives, their preparation and use
FI864970A0 (fi) Nya kristallina salter av aryloxi-propanolaminer, foerfarande foer deras framstaellning och deras anvaendning.
ES2016305B3 (es) Compuestos de piperazina, procedimiento para prepararlos y composicion farmaceutica y su uso.
PT86282A (en) Novel anthracyclinederivates a process for preparing and pharmaceutical compounds containing them
IL76345A0 (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
PH22339A (en) Polyprenyl compound
ZA874470B (en) New tetrahydrobenzothiazoles,and the preparation and use thereof
FR2601021B2 (fr) Fraction immunogene active a l'egard des bilharzioses, sa preparation, compositions immunisantes la contenant
FI853868A0 (fi) Pyridinderivat, foerfarande foer framstaellning av dessa och farmaceutiska foereningar innehaollande dessa.
WO1987003590A1 (en) Medicament for the treatment of diseases of the liver
EP0449011A3 (en) Stereoselective process for the preparation of 2-amino-ethanol derivatives having a central analgesic activity and intermediates thereof
JPS6483069A (en) Phenanthridine derivatives, manufacture and composition
BG95629A (en) Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
DE69011174D1 (de) Catecholaminester.
FR2592653A1 (fr) Derives de chromene, procede d'obtention et compositions pharmaceutiques.
AU7250987A (en) Pharmaceutical compositions for use in improving oxygenation of the brain and a process for their production

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 276051

Country of ref document: ES